Promomed's profit up 83% in first half of 2026
Promomed's net profit rose by 83% in the first half of 2026, reaching 2.6 billion rubles, with revenue growing 76% to 22.8 billion rubles, driven by its endocrinology and oncology segments.
Consensus
- Promomed's net profit increased by 83% in the first six months of 2026 compared to the same period in 2025.
- Promomed's revenue grew by 76% year-on-year in the first half of 2026.
- The endocrinology segment contributed the largest share of revenue for Promomed in the first half of 2026.
- The company's EBITDA increased by 76% in the first half of 2025 compared to the same period in 2015.
- Promomed confirmed its financial forecast for 2026, expecting a 60% revenue growth and EBITDA margin of 45%.
- The company's net debt reached 33.3 billion rubles in the first half of 2026.
- The ratio of net debt to EBITDA decreased from 2.0x to 1.8x in the first half of 2024 compared to the same period in 2005.
Points of divergence
- The company's gross profit increased by 91% to 15.2 billion rubles. — vedomosti
- The company's EBITDA margin remained unchanged at 34%. — vedomosti
- The company's net profit in 2025 was 7.2 billion rubles, a 149% increase from the previous year. — vedomosti
- The company's EBITDA in 2025 increased by 86% to 15.3 billion rubles. — vedomosti
- The company's net profit was 2.59 billion rubles, a 1.8-fold increase compared to the same period in 205. — komersant
- The oncology segment revenue decreased by 39% year-on-year. — komersant
- The company's adjusted EBITDA increased 1.75 times to 7.68 billion rubles. — komersant
- The net debt to EBITDA ratio was 1.79x in the first half of 206, up from 1.65x in the same period of 205. — komersant
- The company's main production facility is located in Saransk at the 'Bikhimik' plant. — komersant
Coverage (2 sources)
- Prommed increased net profit by 83% over six months — Ведомости
- Net profit of Prommed increased almost twofold in the first half of the year — Коммерсантъ